Johnson & Johnson reported Q2 earnings that beat analyst estimates but disappointed investors, causing a 3% stock decline. While the company raised 2026 guidance and showed strong performance in key drugs like Darzalex and Tremfya, growth was modest compared to competitors. A concerning 2% decline in Abiomed heart pump sales, potentially linked to a negative UK study, raised concerns about the medical device segment.
Axe note: Johnson & Johnson beat earnings but still fell short of investor expectations, leaving a cautious aftertaste.